EMA begins analyzing Bavarian Nordic's vaccine against monkeypox

Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.
Photo: Lukas Barth/Reuters/Ritzau Scanpix
Photo: Lukas Barth/Reuters/Ritzau Scanpix
by christopher due karlsson, translated by daniel pedersen

The European Medicines Agency (EMA) has begun a risk/benefit analysis of using Danish biotech firm Bavarian Nordic’s smallpox vaccine against monkeypox, according to a press release from Sweden’s prime minister’s office.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading